ACP-autoantibody response in patients with early rheumatoid arthritis

• Conditions: M05; M06; Seropositive rheumatoid arthritis; Other rheumatoid arthritis

• Registration Number: DRKS00019198
• Lead Sponsor: Department Innere Medizin Klinik für Rheumatologie und Klinische Immunologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-05
• Study Completion: 2022-02-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

Early rheumatoid arthritis with the diagnosis made less than 2 years before inclusion

Exclusion Criteria

Prior therapy with rituximab or cyclophosphamide

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint for this study is the change of ACPA (anti citrullinated protein antibodies) titers in the blood of early-stage rheumatoid arthritis patients 12 months after study entry.

Secondary Outcome Measures

Name	Time	Method
Changes in ACPA-Isotypes, ACPA-subclasses and the B cell receptor repertoire in patients with early rheumatoid Arthritis 12 months after study entry.